🚀 VC round data is live in beta, check it out!
IO Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for IO Biotech and similar public comparables like Vistagen Therapeutics, Skye Bioscience, Marker Therapeutics, AlzeCure Pharma and more.
IO Biotech Overview
About IO Biotech
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Founded
2021
HQ
Employees
80
Website
Sectors
Financials (LTM)
EV
$11M
IO Biotech Financials
IO Biotech reported last 12-month revenue of — and negative EBITDA of ($73M).
In the same LTM period, IO Biotech generated — in gross profit, ($73M) in EBITDA losses, and had net loss of ($68M).
Revenue (LTM)
IO Biotech P&L
In the most recent fiscal year, IO Biotech reported revenue of — and EBITDA of ($94M).
IO Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($73M) | XXX | ($94M) | XXX | XXX | XXX |
| Net Profit | ($68M) | XXX | ($95M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
IO Biotech Stock Performance
IO Biotech has current market cap of $24M, and enterprise value of $11M.
Market Cap Evolution
IO Biotech's stock price is $0.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11M | $24M | 0.0% | XXX | XXX | XXX | $-1.33 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIO Biotech Valuation Multiples
IO Biotech trades at (0.2x) EV/EBITDA.
IO Biotech Financial Valuation Multiples
As of March 18, 2026, IO Biotech has market cap of $24M and EV of $11M.
Equity research analysts estimate IO Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IO Biotech has a P/E ratio of (0.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $24M | XXX | $24M | XXX | XXX | XXX |
| EV (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV/EBITDA | (0.2x) | XXX | (0.1x) | XXX | XXX | XXX |
| EV/EBIT | (0.2x) | XXX | (0.1x) | XXX | XXX | XXX |
| P/E | (0.4x) | XXX | (0.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified IO Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
IO Biotech Margins & Growth Rates
IO Biotech's revenue in the last fiscal year grew by —.
IO Biotech's revenue per employee in the last FY averaged $0.0M.
IO Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (16%) | XXX | (21%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
IO Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vistagen Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Skye Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Marker Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| AlzeCure Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Argenica Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IO Biotech M&A Activity
IO Biotech acquired XXX companies to date.
Last acquisition by IO Biotech was on XXXXXXXX, XXXXX. IO Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by IO Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIO Biotech Investment Activity
IO Biotech invested in XXX companies to date.
IO Biotech made its latest investment on XXXXXXXX, XXXXX. IO Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by IO Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout IO Biotech
| When was IO Biotech founded? | IO Biotech was founded in 2021. |
| Where is IO Biotech headquartered? | IO Biotech is headquartered in Denmark. |
| How many employees does IO Biotech have? | As of today, IO Biotech has over 80 employees. |
| Who is the CEO of IO Biotech? | IO Biotech's CEO is Mai-Britt Zocca. |
| Is IO Biotech publicly listed? | Yes, IO Biotech is a public company listed on Nasdaq. |
| What is the stock symbol of IO Biotech? | IO Biotech trades under IOBT ticker. |
| When did IO Biotech go public? | IO Biotech went public in 2021. |
| Who are competitors of IO Biotech? | IO Biotech main competitors are Vistagen Therapeutics, Skye Bioscience, Marker Therapeutics, AlzeCure Pharma. |
| What is the current market cap of IO Biotech? | IO Biotech's current market cap is $24M. |
| Is IO Biotech profitable? | No, IO Biotech is not profitable. |
| What is the current EBITDA of IO Biotech? | IO Biotech has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of IO Biotech? | Current EBITDA multiple of IO Biotech is (0.2x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.